Flualprazolam

Total Page:16

File Type:pdf, Size:1020Kb

Flualprazolam Flualprazolam: Report of an Outbreak of a New Psychoactive Substance in Adolescents Adam Blumenberg, MD, MA,a Adrienne Hughes, MD,a Andrew Reckers, BA,b Ross Ellison, BS,b Roy Gerona, PhDb Flualprazolam is a nonregistered drug in the benzodiazepine family and abstract constitutes a new psychoactive substance (NPS). Since 2014, a growing number of designer benzodiazepines have become available over the Internet and on the counterfeit drug market. In June 2019, a cluster of patients intoxicated with flualprazolam was identified by the Oregon Poison Center. As an emerging drug of abuse, the clinical characteristics of flualprazolam have been poorly characterized thus far. Over a one-week period, 6 teenagers aDepartment of Emergency Medicine, School of Medicine, Oregon Health and Science University, Portland, Oregon; and presented to local emergency departments after ingesting illegally obtained bClinical Toxicology and Environmental Biomonitoring counterfeit alprazolam, which led to sedation. Other symptoms included Laboratory, University of California, San Francisco, San slurred speech, confusion, and mild respiratory depression. All 6 patients Francisco, California had resolution of their symptoms within 6 hours of ingestion. Blood and Dr Blumenberg conceptualized, researched, wrote, urine samples, as well as a tablet fragment, were obtained from 3 and edited the manuscript; Dr Hughes helped conceptualize and wrote sections of the manuscript; patients. The tablet and biological samples were analyzed by using liquid Mr Ellison and Mr Reckers analyzed and interpreted chromatography–quadrupole time-of-flight mass spectrometry and were analytes, wrote sections of the manuscript, and found to contain the NPS flualprazolam without other drugs or intoxicants. helped edit the manuscript; Dr Gerona analyzed and interpreted analytes, wrote sections of the With this case series, we add to the medical literature a clinical description manuscript, researched, and helped edit the of an emerging drug of abuse. Flualprazolam appears to share the clinical manuscript; and all authors approved the final properties of other benzodiazepines. As flualprazolam and other NPSs manuscript as submitted and agree to be accountable for all aspects of the work. become more common, physicians must be aware of their availability and DOI: characteristics. Sedation lasting ,6 hours was observed in 6 of 6 patients https://doi.org/10.1542/peds.2019-2953 exposed to flualprazolam. No effects that would be unexpected from Accepted for publication Dec 30, 2019 benzodiazepine intoxication were seen among the patients. Specifically, none Address correspondence to Adam Blumenberg, MD, MA, Emergency Medicine and Toxicology, Oregon developed prolonged symptoms or required intubation and mechanical Health and Science University, 3181 SW Sam Jackson ventilation, ICU admission, or antidotal therapy. Park Rd, Portland, OR. E-mail: adamblumenbergmd@ gmail.com PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). In June 2019, the Oregon Poison The benzodiazepine class of drugs bind Copyright © 2020 by the American Academy of Center identified an outbreak of to g-aminobutyric acid A (GABA-A) Pediatrics central nervous system (CNS) receptors, leading to CNS depression. FINANCIAL DISCLOSURE: The authors have indicated depression among adolescents. Unlike barbiturates, which stimulate they have no financial relationships relevant to this The patients developed symptoms the GABA-A receptor directly, article to disclose. at school and required evaluation benzodiazepines enhance the effect of FUNDING: No external funding. and treatment at local emergency GABA on its receptor through allosteric POTENTIAL CONFLICT OF INTEREST: The authors have departments. Further assessment modulation. This leads to enhanced indicated they have no potential conflicts of interest revealed intoxication with chloride permeability in the to disclose. a new psychoactive substance postsynaptic neuron, subsequent (NPS) colloquially referred to hyperpolarization, and diminished To cite: Blumenberg A, Hughes A, Reckers A, as “Hulk,” which on analysis, was probability of generating an action et al. Flualprazolam: Report of an Outbreak of revealed to be the benzodiazepine potential.1 Whereas overdose of opioids a New Psychoactive Substance in Adolescents. Pediatrics. 2019;146(1):e20192953 flualprazolam. or barbiturates often leads to Downloaded from www.aappublications.org/news by guest on September 28, 2021 PEDIATRICS Volume 146, number 1, July 2019:e20192953 CASE REPORT respiratory depression or apnea, the classic benzodiazepine toxidrome is a coma with normal vital signs. Chlordiazepoxide, the first benzodiazepine, was synthesized because of demand for a sedative with less risk of respiratory depression. Subsequent benzodiazepines, such as diazepam, were created via modification of chlordiazepoxide’s molecular structure.2 Death from isolated benzodiazepine toxicity is rare; FIGURE 1 however, in combination with alcohol, Comparative structures of flualprazolam, triazolam, and alprazolam. opioids, or other sedatives, death from respiratory depression or aspiration is more common.3 benzodiazepines.9 Although common reported clinical findings. flualprazolam has not been studied One individual (patient 3) developed Flualprazolam is a nonregistered drug directly, rat studies of fluorinated mild respiratory depression in the benzodiazepine family and diazepam analogues vary in potency (respiratory rate of 10 breaths per constitutes an NPS.4 Since the early from one-half to 10-fold10; therefore, minute) that was unresponsive to 2000s, there has been a rise in the the pharmacodynamic effects of 0.4-mg naloxone, which was given rate of NPS exposures worldwide fluorinated alprazolam cannot be empirically because of the unknown because of Internet purchasing. surmised on the basis of chemical identity of the drug. Two of the 6 There have been .800 unique NPSs structure alone. patients (patients 2 and 6) were reported to the United Nations Office initially drowsy but asymptomatic at on Drugs and Crime between 2009 11 fi fl Mei et al identi ed ualprazolam the time of evaluation. All patients and 2017 and 22 tons of NPS seized in postmortem blood; however, at who were symptomatic recovered by law enforcement in 2016 alone.5 present, there are no data on the within 6 hours, and all were Typically, NPSs are synthesized by clinical effects or pharmacology of discharged from the hospital’s simple structural modification or fl ualprazolam. Correlations between emergency department. substitution of existing recreational dose and response, duration of action, drugs, pharmaceuticals, or their metabolism, and onset of action are 6 active metabolites. In the United unknown. In this case series, we add ANALYSIS States, the incidence of exposures to fi to the medical literature the rst A urine immunoassay (MEDTOX designer benzodiazepines in fi description of con rmed clinical PROFILE-V; MEDTOX Diagnostics, particular has been rising since fl ualprazolam intoxication. Inc., Burlington, NC) for common 2014.7 drugs of abuse was performed in 5 Flualprazolam is structurally patients, all of whom tested positive CASES related to the US Food and Drug for benzodiazepines (detection Administration–approved Over a 7-day period, 6 teenagers were threshold 150 ng/mL nordiazepam). pharmaceuticals alprazolam and transported to local emergency The results of a urine test for triazolam, differing in chemical departments from a single high patient 1 were also positive for composition by the presence of school after ingesting an illegally cannabinoids (detection threshold a fluorine atom on the ortho obtained substance colloquially 50 ng/mL; 11-nor-9-carboxy-d-9- position of the phenyl moiety, as named Hulk. All 6 received the drug tetrahydrocannabinol). A pale green seen in Fig 1. All 3 compounds are as a free sample from a single tablet in the possession of patient 3 triazolobenzodiazepines.8 As student, believing that the substance had the markings “S903,” which is a benzodiazepine, expected clinical was commercial Xanax. The clinical intended to identify the tablet as 2 mg effects of flualprazolam would characteristics and laboratory results of alprazolam. An analysis of a tablet include sedation, anxiolysis, amnesia, for the patients who were exposed fragment (Fig 2) in the possession and potentially respiratory are summarized in Table 1. Five of of patient 6 revealed that the depression. In overdose, alprazolam the patients were boys; their ages tablet contained 2.77 mg/g of appears to have greater toxicity than ranged from 14 to 16 years. Lethargy flualprazolam, or ∼2.75 to 3 mg of other pharmaceutical and slurred speech were the most flualprazolam per intact tablet. No Downloaded from www.aappublications.org/news by guest on September 28, 2021 2 BLUMENBERG et al TABLE 1 Clinical and Laboratory Characteristics of Patients Intoxicated With Flualprazolam Patient Age Sex Clinical Presentation at Emergency Department Urine Immunoassay for Drugs of Flualprazolam No. Abuse Concentration (LC- QTOF/MS) 1 16 Male Lethargy and slurred speech Positive for benzodiazepines and Urine: 72.1 ng/mL cannabinoids 2 15 Male Asymptomatic Not obtained Not obtained 3 16 Male CNS depression, slurred speech, and mild respiratory depression Positive for benzodiazepines Urine: 19.4 ng/mL unresponsive to 0.4-mg intravenous naloxone Blood: 14.6 ng/mL 4 16 Female Lethargy and slurred speech Positive for benzodiazepines Urine: 3.0 ng/mL 5 14 Male Lethargy and confusion Positive for benzodiazepines
Recommended publications
  • Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin Healthcare
    Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin healthcare 4/22/2020 Overview benzodiazepines • Examples of benzos and benzo like drugs • Indications for benzos • Pharmacology of benzos • Side effects and contraindications • Benzo withdrawal • Benzo tapers 12/06/2018 Sedative/Hypnotics • Benzodiazepines • Alcohol • Z-drugs (Benzo-like sleeping aids) • Barbiturates • GHB • Propofol • Some inhalants • Gabapentin? Pregabalin? 12/06/2018 Examples of benzodiazepines • Midazolam (Versed) • Triazolam (Halcion) • Alprazolam (Xanax) • Lorazepam (Ativan) • Temazepam (Restoril) • Oxazepam (Serax) • Clonazepam (Klonopin) • Diazepam (Valium) • Chlordiazepoxide (Librium) 4/22/2020 Sedatives: gaba stimulating drugs have incomplete “cross tolerance” 12/06/2018 Effects from sedative (Benzo) use • Euphoria/bliss • Suppresses seizures • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Sleep inducing • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 Tolerance to benzo effects? • Effects quickly diminish with repeated use (weeks) • Euphoria/bliss • Suppresses seizures • Effects incompletely diminish with repeated use • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Seep inducing • Durable effects with repeated use • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 If you understand this pharmacology you can figure out the rest... • Potency • 1 mg diazepam <<< 1 mg alprazolam • Duration of action • Half life differences • Onset of action • Euphoria, clinical utility in acute
    [Show full text]
  • Test Update Immediate Action Notification
    Effective Date: Monday, April 27, 2020 Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, April 27, 2020 Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS Labs 200 Welsh Rd. Horsham, PA 19044-2208 [email protected] Page 1 of 6 Effective Date: Monday, April 27, 2020 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments Designer Benzodiazepines (Qualitative), 0570U • Urine (Forensic) Designer Benzodiazepines Confirmation 52487U • (Qualitative), Urine Designer Benzodiazepines Confirmation, 52487B • Blood Designer Benzodiazepines Confirmation, 52487SP • Serum/Plasma Designer Benzodiazepines, Blood 0570B • (Forensic) Designer Benzodiazepines, 0570SP • Serum/Plasma (Forensic) NMS Labs 200 Welsh Rd.
    [Show full text]
  • The Toxicology Panel -17Th Nysam (Virtual) Conference 2021
    THE TOXICOLOGY PANEL -17TH NYSAM (VIRTUAL) CONFERENCE 2021 MODERATOR: TIMOTHY J. WIEGAND, MD, FACMT, FAACT, DFASAM JoAn Laes, MD Addiction Medicine Faculty Hennepin County Medical Center, Minneapolis, MN Lewis Nelson, MD, FACMT Chair, Department of Emergency Medicine, Rutgers New Jersey Medical School Jeanmarie Perrone, MD Director of Division of Medical Toxicology & Penn Center PANELISTS for Addiction Medicine and Policy Ross Sullivan, MD Director SUNY Upstate Emergency Bridge Clinic & Medical Director Helio Health, Syracuse, NY Paul Wax, MD, FACMT Executive Director the American College of Medical Toxicology CONFLICT OF NONE OF OUR SPEAKERS HAVE ANY CONFLICTS OF INTEREST INTEREST TO DISCLOSE A 27 year-old M with history of opioid and sedative use disorder had been doing well in an outpatient treatment program with mix of counseling and treatment with buprenorphine/naloxone. CASE 1 He entered the program about 9 months prior after a 28 day combined detoxification/inpatient facility stay where he was transitioned from heroin/fentanyl (“10 bags/day”) to the buprenorphine and “detoxified” from 2-4 mg alprazolam and/or 2-4 mg clonazepam daily. CASE 1 About 9 months into the program he is found sleeping at work by his boss and when awoke he is slurring his speech and has trouble walking. This was a job he’d lost prior to treatment but they had let him back in 3 months after starting in treatment after he demonstrated sobriety –he worked with his father in a recycling plant coordinating large shipments and sometimes picking up materials using heavy equipment and other machinery. He lives with his parents and they are quite upset about the incident but he states, “I wasn’t using I was just tired!” CASE 1 The parents communicate with his counselor and he is brought in for a urine drug test –which initially tests positive for benzodiazepines but the confirmation is negative.
    [Show full text]
  • Benzodiazepine Group ELISA Kit
    Benzodiazepine Group ELISA Kit Benzodiazepine Background Since their introduction in the 1960s, benzodiazepines have been widely prescribed for the treatment of anxiety, insomnia, muscle spasms, alcohol withdrawal, and seizure-prevention as they are depressants of the central nervous system. Despite the fact that they are highly effective for their intended use, benzodiazepines are prescribed with caution as they can be highly addictive. In fact, researchers at NIDA (National Institute on Drug Abuse) have shown that addiction for benzodiazepines is similar to that of opioids, cannabinoids, and GHB. Common street names of benzodiazepines include “Benzos” and “Downers”. The five most encountered benzodiazepines on the illicit market are alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), and temazepam (Restori). The method of abuse is typically oral or snorted in crushed form. The DEA notes a particularly high rate of abuse among heroin and cocaine abusers. Designer benzodiazepines are currently offered in online shops selling “research chemicals”, providing drug abusers an alternative to prescription-only benzodiazepines. Data defining pharmacokinetic parameters, drug metabolisms, and detectability in biological fluids is limited. This lack of information presents a challenge to forensic laboratories. Changes in national narcotics laws in many countries led to the control of (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries. With the control of phenazepam and etizolam, clandestine laboratories have begun researching and manufacturing alternative benzodiazepines as legal substitutes. Delorazepam, diclazepam, pyrazolam, and flubromazepam have emerged as compounds in this class of drugs. References Drug Enforcement Administration, Office of Diversion Control. “Benzodiazepines.” http://www.deadiversion.usdoj.gov/drugs_concern/benzo_1.
    [Show full text]
  • WHO Expert Committee on Drug Dependence
    WHO Technical Report Series 1034 This report presents the recommendations of the forty-third Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of psychoactive substances for possible scheduling under the International Drug Control Conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm of each substance. The ECDD advises the Director-General of WHO to reschedule or to amend the scheduling status of a substance. The Director-General will, as appropriate, communicate the recommendations to the Secretary-General of the United Nations, who will in turn communicate the advice to the Commission on Narcotic Drugs. This report summarizes the findings of the forty-third meeting at which the Committee reviewed 11 psychoactive substances: – 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT) WHO Expert Committee – 3-Fluorophenmetrazine (3-FPM) – 3-Methoxyphencyclidine (3-MeO-PCP) on Drug Dependence – Diphenidine – 2-Methoxydiphenidine (2-MeO-DIPHENIDINE) Forty-third report – Isotonitazene – MDMB-4en-PINACA – CUMYL-PEGACLONE – Flubromazolam – Clonazolam – Diclazepam The report also contains the critical review documents that informed recommendations made by the ECDD regarding international control of those substances. The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO’s constitutional functions is to provide objective, reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Flualprazolam Sample Type: Biological Fluid
    Flualprazolam Sample Type: Biological Fluid Latest Revision: June 25, 2019 Date of Report: June 25, 2019 1. GENERAL INFORMATION IUPAC Name: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine InChI String: InChI=1S/C17H12ClFN4/c1-10-21-22-16-9-20-17(12-4-2-3-5- 14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 CFR: Not Scheduled (06/2019) CAS# 28910-91-0 Synonyms: 2’-Fluoro Alprazolam, ortho-Fluoro Alprazolam Source: NMS Labs – Toxicology Department 2. CHEMICAL DATA Chemical Molecular Molecular Exact Mass Analyte Formula Weight Ion (M) [M+H]+ Flualprazolam C17H12ClFN4 326.75 326 327.0807 Important Note: All identifications were made based on evaluation of analytical data (LC-QTOF) in comparison to analysis of acquired reference material. Report Prepared By: Alex J. Krotulski, MSFS, and Barry K. Logan, PhD, F-ABFT 3. SAMPLE HISTORY Flualprazolam has been identified in three cases since March 2018. The geographical and demographic breakdown is below: Geographical Location: Pennsylvania (n=2), Indiana (n=1) Biological Sample: Blood (n=3) Date of First: Collection: March 8, 2018 Receipt: March 10, 2018 Date of Most Recent: Collection: June 3, 2019 Receipt: June 7, 2019 Additional NPS: Etizolam (n=2), Clonazolam (n=1), Flubromazolam (n=1) 4. BRIEF DESCRIPTION Flualprazolam is classified as a novel benzodiazepine, although its synthesis and activity have been previously described in the literature.1 Benzodiazepines are central nervous system depressants. Novel benzodiazepines, often pirated from early drug discovery or pharmaceutical studies, have appeared on novel and illicit drug markets in recent years.
    [Show full text]
  • Flualprazolam Article Originally Appeared in TOXTALK®, Volume 43, Issue 4
    Donna Papsun¹, MS, D-ABFT-FT, Craig Triebold², F-ABC, D-ABFT-FT Emerging Drug: ¹NMS Labs, Horsham, PA; ²Sacramento County District Attorney Laboratory of Forensic Services, Sacramento, CA Flualprazolam Article originally appeared in TOXTALK®, Volume 43, Issue 4 In recent years, there has been an increase of misuse related to designer benzodiazepines (DBZD), a subcategory of novel psychoactive substances (NPS). Benzodiazepines are commonly prescribed for their anxiolytic, muscle relaxant, sedative- hypnotic, and anticonvulsant properties, but due to their widespread availability and relatively low acute toxicity, there is a high potential for misuse and dependence. Therefore, in the era of analogs of commonly used substances emerging on the drug market as suitable alternatives, it is not unexpected that designer variants of benzodiazepines have become available and in demand. Compounds of this class may have either been repurposed from pharmaceutical research, chemically modified from prescribed benzodiazepines, or obtained from diversion of pharmaceuticals available in other countries. Flualprazolam, a fluorinated analog of alprazolam, is an emerging designer benzodiazepine with increasing prevalence, which is an example of a modification to a prescribed benzodiazepine. It was first patented in the 1970s but never marketed, so it has been repurposed for recreational abuse from pharmaceutical research as well (1). Its chemical characteristics and structure are listed in Figure 1. Flualprazolam is a high potency triazolo-benzodiazepine with sedative effects similar to other benzodiazepines (2). It is marketed by internet companies for “research purposes” as an alternative to alprazolam and discussions on online forums suggest that flualprazolam lasts longer and is stronger than alprazolam, its non-fluorinated counterpart (3).
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • 1 'New/Designer Benzodiazepines'
    1 ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports 2 Laura Orsolini*1,2,3, John M. Corkery1, Stefania Chiappini1, Amira Guirguis1, Alessandro Vento4,5,6,7, 3 Domenico De Berardis3,8,9, Duccio Papanti1, and Fabrizio Schifano1 4 5 1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical 6 Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK. 7 2 Neomesia Mental Health, Villa Jolanda Hospital, Jesi, Italy. 8 3 Polyedra, Teramo, Italy. 9 4 NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University – Rome, School of 10 Medicine and Psychology; Sant’Andrea Hospital, Rome, Italy 11 5 School of psychology - G. Marconi Telematic University, Rome, Italy 12 6 Addictions Observatory (ODDPSS), Rome, Italy 13 7 Mental Health Department - ASL Roma 2, Rome, Italy 14 8 Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University of “G. D’Annunzio”, Chieti, 15 Italy. 16 9 NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4 17 Teramo, Italy. 18 19 Corresponding author: 20 Laura Orsolini, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life 21 and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK; Villa Jolanda Hospital, Neomesia 22 Mental Health, Villa Jolanda, Italy; Polyedra, Teramo, Italy; E-mail address: [email protected]. Tel.: (+39) 392 23 3244643. 24 25 Conflicts of Interest 26 The authors declare that this research was conducted in the absence of any commercial or financial relationships 27 that could be construed as a potential conflict of interest.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]